FDA Therapeutic Equivalency Codes: How Laws Determine Which Generic Drugs Can Be Substituted

When you pick up a prescription at the pharmacy, you might not realize that a legal system is quietly deciding whether you get the brand-name drug or a cheaper generic. That system? FDA therapeutic equivalency codes. These aren't just technical labels-they're the legal backbone of drug substitution in the U.S., and they directly affect your out-of-pocket costs and access to medicine.

Every generic drug approved by the FDA gets a code, usually two letters like 'AA' or 'AB'. These codes tell pharmacists and state boards whether the generic can legally replace the brand-name version. It's not enough that the generic has the same active ingredient. The FDA requires proof that it works the same way in your body, delivers the same dose at the same rate, and produces the same clinical effect. Only then does it earn an 'A' rating-and the legal right to be swapped in without a doctor's approval.

What the 'A' and 'B' Codes Really Mean

The first letter of the TE code is the most important. If it's an 'A', the generic is considered therapeutically equivalent to the brand-name drug. That means you can swap it without worry. If it's a 'B', the FDA says there's not enough evidence to confirm it works the same way. You might still get the 'B' drug if your doctor writes for it specifically, but your pharmacist can't substitute it on their own.

Here’s how it breaks down:

• 'AA' = Immediate-release oral pills with no bioequivalence concerns. These are the most common generics-think generic versions of Lipitor or metformin.
• 'AB' = Products that had initial bioequivalence questions but later proved equivalent. This often happens when the FDA gets more data after approval.
• 'B' = Any code starting with 'B' means substitution isn't allowed under state law. This includes 'BC' (extended-release), 'BD' (bioequivalence problems), 'BT' (topical creams), 'BN' (nebulized inhalers), and others.

There's a reason 'B' codes exist. Some drugs are incredibly complex. A cream, an inhaler, or a long-acting injection doesn't behave the same way in the body as a simple pill. Two generics of the same drug might have different inactive ingredients or manufacturing processes that affect how the medicine is absorbed. The FDA doesn't assume they're the same-it requires hard data.

How the Law Makes Substitution Real

The FDA assigns the codes, but the law that lets pharmacists swap drugs comes from the states. All 50 states base their substitution rules on the Orange Book-the FDA's official list of therapeutic equivalency ratings. If a drug has an 'A' code, state laws almost always allow substitution. If it's a 'B', substitution is prohibited.

For example, California's pharmacy law says pharmacists can substitute only if the generic has an 'A' rating. New York requires pharmacists to check the current Orange Book before swapping. In Texas, the law is even stricter: if the prescriber writes "Do Not Substitute," the pharmacist must honor that-even if the generic has an 'A' code.

This legal patchwork means your ability to get a generic depends on where you live. But the common thread? The FDA's TE code is the gatekeeper. Without it, state laws wouldn't have a clear standard to follow.

Why This System Saves Billions

Therapeutic equivalency codes aren't just about safety-they're about cost. Since the system was expanded after the 1984 Hatch-Waxman Act, generics have saved the U.S. healthcare system more than $1.7 trillion. In 2022 alone, drugs with 'A' codes saved $298 billion.

How? When a generic gets an 'A' rating, pharmacists can swap it automatically. That drives competition. Brand-name companies lose market share fast. Prices drop. Patients pay less. Pharmacies benefit. Insurers save money. It’s a ripple effect that lowers costs at every level.

But here's the catch: only 62% of FDA-approved drugs have 'A' codes. That means nearly a quarter of approved generics still can't be substituted. Many of those are complex drugs-inhaled steroids, injectable biologics, topical treatments for eczema or psoriasis. These are expensive to develop, and proving bioequivalence is harder than with a simple pill.

The Hidden Struggle Behind 'B' Codes

You might wonder: if a drug is FDA-approved, why isn't it automatically 'A'? The answer is messy. Sometimes, the generic manufacturer doesn't submit enough data. Other times, the science is still evolving. A cream that works on one person's skin might not work the same on another's. An inhaler's particle size matters. A slow-release tablet's coating affects absorption.

That's why 'B' codes persist. In 2023, 24.3% of listed products carried 'B' ratings. Pharmacists report real hesitation. A 2023 survey found 68% of pharmacists avoid substituting 'BT' (topical) or 'BN' (nebulizer) products because they’ve seen patients have inconsistent responses.

Brand-name companies have used this uncertainty to their advantage. In 2022, the FDA received 1,247 citizen petitions challenging TE codes-up 17% from the year before. Many were filed to delay generic entry. The system, while effective, is under pressure.

What’s Changing Now?

The FDA knows the system needs updating. In 2023, it launched a major push to reduce the number of 'B' codes. Its Complex Generic Drug Initiative is focused on improving testing methods for inhalers, creams, injections, and other tricky products.

The goal? Get 'B' code products down from 24.3% to under 15% by 2027. That means more generics will qualify for substitution, more patients will save money, and fewer people will be stuck with expensive brand-name drugs.

One big change: the FDA now accepts minor formulation differences-like different fillers or coatings-as long as the drug performs the same in the body. That opens the door for more generics to earn 'A' ratings.

Also, the Orange Book is now digital. Pharmacists can access it via API through their pharmacy systems. That means real-time updates. No more waiting for a printed book. If a new 'A' code is assigned, your pharmacy system gets the update automatically.

What You Need to Know as a Patient

If your prescription says "brand necessary," ask why. Is it because the drug has a 'B' code? Or is it just habit? Many doctors still default to brand names out of caution-even when a generic has an 'A' rating.

Check your pill. If you're on a generic, look at the name. If it's the same active ingredient as the brand, and your pharmacy didn't ask for permission to swap it, you're likely on an 'A' rated product.

And if you're switching from a brand to a generic, pay attention. Some people notice differences in side effects or effectiveness-even with 'A' rated drugs. That doesn't mean the code is wrong. It means your body reacts differently. Talk to your doctor or pharmacist. Don't assume it's a problem with the drug.

Bottom line: FDA therapeutic equivalency codes are the invisible hand that makes affordable generics possible. They're not perfect, but they're the best system we have. And they're getting better.